Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology - Basic: Basic Science

The ratio of maximum percent tumor accumulations of pretargeting agent and radiolabeled effector does not change with tumor size

Guozheng Liu, Shuping Dou, Minmin Liang, Xiangji Chen, Mary Rusckowski and Donald Hnatowich
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1564;
Guozheng Liu
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuping Dou
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minmin Liang
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiangji Chen
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Rusckowski
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald Hnatowich
1University of Massachusetts Medical School, Worcester, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1564

Objectives The optimal dosage ratio of antibody to effector in pretargeting is proportional to the ratio of their maximum percent tumor accumulations (MPTAs). As a complication to dosage optimization, each MPTA varies with tumor size differently. However, if it can be shown that the ratio of MPTAs is a constant with tumor size, the optimal dosage ratio determined for one tumor size will be applicable to all others, thereby greatly simplifying dosage optimization.

Methods After the dosage range providing the MPTAs of the 111In labeled pretargeting antibody antiTAG72 CC49 was located, the MPTAs were measured in the LS174T tumored mice bearing different size tumors. The influence of tumor size on the MPTAs of the effector, 99mTc-cMORF, was determined by collecting the results of previous studies. In both cases, the MPTAs vs tumor sizes were fitted non-linearly with the same power function.

Results The best fit of the antibody MPTA (y) with tumor size (x) was y=18.99 x -0.65 while that for the effector was y=4.51 x -0.66. Thus even though the MPTAs of both change dramatically with tumor size, the ratio remains constant.

Conclusions The MPTA ratio of antibody to effector is a constant of tumor size. Optimization will be greatly simplified since the optimum dosage ratio does not require remeasurement for different tumor sizes. Theoretical considerations suggest that this relationship will also hold for alternative antibodies and effectors but this must be confirmed.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The ratio of maximum percent tumor accumulations of pretargeting agent and radiolabeled effector does not change with tumor size
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The ratio of maximum percent tumor accumulations of pretargeting agent and radiolabeled effector does not change with tumor size
Guozheng Liu, Shuping Dou, Minmin Liang, Xiangji Chen, Mary Rusckowski, Donald Hnatowich
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1564;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The ratio of maximum percent tumor accumulations of pretargeting agent and radiolabeled effector does not change with tumor size
Guozheng Liu, Shuping Dou, Minmin Liang, Xiangji Chen, Mary Rusckowski, Donald Hnatowich
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1564;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology - Basic: Basic Science

  • The change of F-18 FDG and H-3 PCV uptakes after transduction of micro RNA for hexokinase II and HSV1-sr39 gene in cancer cells
  • Radiolabeled inhibitors of seprase targeting the tumor microenvironment
  • Transcriptome foundations of low FDG uptake in prostate cancer
Show more Oncology - Basic: Basic Science

Basic Science Posters

  • [131I] ICF01012, a potential agent for targeted radionuclide therapy of melanoma
  • In vitro and in vivo characterization of a new somatostatin (SST) DOTA-conjugated analog
  • The change of F-18 FDG and H-3 PCV uptakes after transduction of micro RNA for hexokinase II and HSV1-sr39 gene in cancer cells
Show more Basic Science Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire